Nuvectis Pharma, Inc. NVCT Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s financing cash flow?
- Nuvectis Pharma, Inc. (NVCT) reported financing cash flow of $7K in Q1 2026.
- How has Nuvectis Pharma, Inc.'s financing cash flow changed year-over-year?
- Nuvectis Pharma, Inc.'s financing cash flow decreased by 100.0% year-over-year, from $15.51M to $7K.
- What is the long-term trend for Nuvectis Pharma, Inc.'s financing cash flow?
- Over 2 years (2023 to 2025), Nuvectis Pharma, Inc.'s financing cash flow has grown at a 38.9% compound annual growth rate (CAGR), from $15.09M to $29.11M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.